Zobrazeno 1 - 10
of 169
pro vyhledávání: '"Julie A. Stone"'
Autor:
Sébastien Bihorel, Youfang Cao, Akshita Chawla, Ruthie Birger, Brian M. Maas, Wei Gao, Stefan Roepcke, Susanne Sardella, Rebecca Humphrey, Sindhuri Kondragunta, Bhuvana Jayaraman, Monika Martinho, Wendy Painter, George Painter, Wayne Holman, Carisa De Anda, Michelle L. Brown, Matthew G. Johnson, Amanda Paschke, Matthew L. Rizk, Julie A. Stone
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 12, Pp 1859-1871 (2023)
Abstract Effective antiviral treatments for coronavirus disease 2019 (COVID‐19) are needed to reduce the morbidity and mortality associated with severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) infection, particularly in patients
Externí odkaz:
https://doaj.org/article/8cddadd8bcca434f80fe87480a247f8a
Autor:
Brian M. Maas, Julie Strizki, Randy R. Miller, Sushma Kumar, Michelle Brown, Matthew G. Johnson, Mickie Cheng, Carisa De Anda, Matthew L. Rizk, Julie A. Stone
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 2, Pp n/a-n/a (2024)
Abstract Molnupiravir is an oral prodrug of the broadly active, antiviral ribonucleoside analog N‐hydroxycytidine (NHC). The primary circulating metabolite NHC is taken up into cells and phosphorylated to NHC‐triphosphate (NHC‐TP). NHC‐TP ser
Externí odkaz:
https://doaj.org/article/80235adabbc14c2b94f7c558ebb6cf63
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2348-2359 (2021)
Abstract Coronavirus disease 2019 (COVID‐19) global pandemic is caused by severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) viral infection, which can lead to pneumonia, lung injury, and death in susceptible populations. Understand
Externí odkaz:
https://doaj.org/article/1ae0f6eb4842422aa0440c30df295216
Autor:
Mark Forman, John Palcza, Jack Tseng, Julie A. Stone, Brittany Walker, Dennis Swearingen, Matthew D. Troyer, Marissa F. Dockendorf
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 5, Pp 545-555 (2019)
β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) is required for the production of β‐amyloid peptides, which are implicated in the etiology of Alzheimer's disease. The safety and pharmacokinetics of the BACE1 inhibitor verubecestat
Externí odkaz:
https://doaj.org/article/d5a82e2a471d464587738eee563b31d1
Autor:
Marianne J. H. van Vugt, Julie A. Stone, “Rik” H. J. M. M. De Greef, Ellen S. Snyder, Leslie Lipka, David C. Turner, Anne Chain, Mallika Lala, Mengyao Li, Seth H. Robey, Anna G. Kondic, Dinesh De Alwis, Kapil Mayawala, Lokesh Jain, Tomoko Freshwater
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the developm
Externí odkaz:
https://doaj.org/article/3069c7c4e0f64562b9cab9bff16d3f3d
Autor:
Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis, Julie A. Stone
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)
Abstract Background Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pembrolizumab studies;
Externí odkaz:
https://doaj.org/article/182d21e5687543179e830a09e90b9fdf
Autor:
Akshita Chawla, Ruthie Birger, Hong Wan, Youfang Cao, Brian M. Maas, Amanda Paschke, Carisa De Anda, Matthew L. Rizk, Julie A. Stone
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:1337-1345
Autor:
Aline Rodrigues de Queiroz, Connor Hines, Jeremy Brown, Seema Sahay, Jithesh Vijayan, Julie M. Stone, Nate Bickford, Melissa Wuellner, Katarzyna Glowacka, Nicole R. Buan, Rebecca L. Roston
Publikováno v:
Phytochemistry Reviews. 22:407-447
Plant growth and resilience require balancing an inherently oxidative metabolism with powerful antioxidant systems that help maintain homeostasis. When the environment changes, reactive oxygen species are potent indicators of that change, allowing ad
Autor:
Julie A. Stone, Dinesh P. de Alwis, Vikram Sinha, Scot W. Ebbinghaus, Jiannan Kang, Kapil Mayawala, Lokesh Jain, Jonathan Wesley Riess, Edward B. Garon, Andrew G. Robinson, Keaven M. Anderson, Anna G. Kondic, David C. Turner
Purpose:To investigate the relationship of pembrolizumab pharmacokinetics (PK) and overall survival (OS) in patients with advanced melanoma and non–small cell lung cancer (NSCLC).Patients and Methods:PK dependencies in OS were evaluated across thre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09f3b10f95f934a74bdc0c2752ee8535
https://doi.org/10.1158/1078-0432.c.6527232
https://doi.org/10.1158/1078-0432.c.6527232
Autor:
Julie A. Stone, Dinesh P. de Alwis, Vikram Sinha, Scot W. Ebbinghaus, Jiannan Kang, Kapil Mayawala, Lokesh Jain, Jonathan Wesley Riess, Edward B. Garon, Andrew G. Robinson, Keaven M. Anderson, Anna G. Kondic, David C. Turner
Fig S1. Kaplan-Meier plots of overall survival, stratified by pembrolizumab dose, demonstrate similarity of efficacy across a 5-fold dose range (2 to 10 mg/kg Q3W) in A) advanced ipilimumab-refractory melanoma, KEYNOTE-002 (Cox HR 0.98; 95% CI 0.94-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f910e21ebcdd3b23a856066a36bafd2
https://doi.org/10.1158/1078-0432.22469358
https://doi.org/10.1158/1078-0432.22469358